Search clinical trials for: Placebo to BI 135585

Total 1456 results

Boehringer Ingelheim

Completed

Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI135585 XX Administered as Tablet and as Solution in Healthy Volunteers

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Completed

Single Rising Dose Study of BI 135585 XX in Health Asian Male Volunteers.

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Bioavailability and Pharmacokinetics of BI 135585 XX Administered as Tablet With and Without Food

Healthy

Germany
Boehringer Ingelheim

Completed

Study to Explore Pharmacokinetics and Pharmacodynamics of a Single Rising Dose of BI 135585 XX

Healthy

Germany
Boehringer Ingelheim

Completed

Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients

Asthma

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects

Healthy | Asthma

Germany
Boehringer Ingelheim

Completed

To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of Single Rising Oral Doses of BI 224436 ZW in Healthy Male Volunteers.

Healthy
Boehringer Ingelheim

Terminated

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses and Effect of Food on the Bioavailability of BI 1060469

Healthy

Germany
Boehringer Ingelheim

Terminated

A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is

Psoriasis

United States, Canada, Germany
Boehringer Ingelheim

Completed

BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 113608 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee

Osteoarthritis

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of Single Rising Oral Doses of BI 1021958 Tablets in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Multiple Rising Dose Study of BI 144807 Powder in Bottle in Mild Asthmatic Patients

Healthy | Asthma

United Kingdom
Boehringer Ingelheim

Completed

Single Rising Dose Study (Intravenous Infusion and Subcutaneous Injection) of BI 655064 in Healthy Male Volunteers

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 187004 CL

Healthy

Germany
Boehringer Ingelheim

Completed

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 163538 XX

Healthy

Germany
Boehringer Ingelheim
Eli Lilly and Company

Completed

Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada, China, France, Germany, India, Korea, Republic of, Mexico, Slovakia, Slovenia, Taiwan, Turkey
Boehringer Ingelheim

Completed

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

Kidney Disease, Chronic

United States, Spain, Korea, Republic of, Belgium, Australia, Hong Kong, India, Canada, China, Germany, Italy, Japan, Malaysia, Finland, Switzerland, Turkey, Hungary, Poland, Portugal, Philippines, Czechia, Greece, Bulgaria, Brazil, Arg... and more
Boehringer Ingelheim

Not yet recruiting

A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity

Obesity
Boehringer Ingelheim

Completed

Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers.

Healthy

Germany
Guang'anmen Hospital of China Academy of Chinese...
Hubei Hospital of Traditional Chinese Medicine; Hebei Yiling Hospital; The First... and other collaborators

Unknown

The Multi-Centric Clinical Study of Chinese Medicine Intervention on Diabetes Distal Symmetric Polyneuropathy.

Type 2 Diabetes Mellitus
Boehringer Ingelheim

Completed

A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479

Healthy

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients

Hepatitis C | Pharmacokinetics

Japan
University of Chicago

Completed

Teaching Use of Respiratory Inhalers (TURI) (TURI)

Asthma | COPD

United States
University of Chicago
CHEST Foundation

Completed

Virtual Teach-to-Goal Education vs. Brief Education for Children (V-TTG vs BI)

Asthma | Shortness of Breath | Bronchospasm

United States
Peking Union Medical College Hospital

Completed

Analyse of Diagnosis Value of Keloid on 68Ga- FAPI-04 PET-CT

Keloid

China
Boehringer Ingelheim

Not yet recruiting

A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity

Healthy
Boehringer Ingelheim

Not yet recruiting

A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men

Healthy
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Well Different Doses of BI 3802876 Are Tolerated

Healthy

Belgium
Boehringer Ingelheim

Recruiting

A Study in Healthy People to Test How Well Repeated Doses of BI 3032950 Are Tolerated

Healthy

Belgium
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease

Diabetic Nephropathies

Spain, Australia, United States, Canada, China, Japan, Malaysia, United Kingdom, Mexico, Portugal, Denmark, Hong Kong, Poland, New Zealand, Argentina, Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0003)

Healthy

Japan
Boehringer Ingelheim

Recruiting

A Study in Healthy Men to Test How Different Doses of BI 3031185 Are Tolerated and How Food Influences the Amount of BI 3031185 in the Blood

Healthy

Germany
Boehringer Ingelheim

Recruiting

IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack (IRI-EXPLORE)

Myocardial Infarction

Germany, Spain, Hungary, United Kingdom, Canada, Australia, Poland, Slovakia, Italy, New Zealand
Boehringer Ingelheim

Completed

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Not yet recruiting

A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim

Recruiting

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

Bronchiectasis

Belgium, Spain, Denmark, Germany, Bulgaria, Japan, United States, Australia, Czechia, France, Hungary, Italy, Korea, Republic of, Latvia, Poland, Canada, Netherlands, Portugal
Boehringer Ingelheim

Active, not recruiting

A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906

Healthy | Obesity

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

This Study Tests How Different Doses of BI 690517 Are Taken up in the Body of Healthy Men. The Study Also Looks at How Food Influences the Amount of BI 690517 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

4 Weeks Treatment of Type II Diabetic Patients With BI 44847

Diabetes Mellitus, Type 2

Germany, Netherlands
Boehringer Ingelheim

Withdrawn

A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2

COVID-19
Boehringer Ingelheim

Recruiting

A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight

Obesity | Overweight

China

3

Subscribe